Goio E, Ielasi L, Benevento F, Renzulli M, Tovoli F. Long-lasting remission in a metastatic hepatocellular carcinoma patient after combined regorafenib therapy and surgery.
Hepat Oncol 2020;
7:HEP24. [PMID:
32774834 PMCID:
PMC7399611 DOI:
10.2217/hep-2020-0014]
[Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
AIMS
The therapeutic scenario of systemic treatments for hepatocellular carcinoma (HCC) is rapidly changing. There is much interest in the possibility of combining new therapies with surgery, but clinical data is lacking. We aimed to provide an example of such integration.
PATIENTS & METHODS
We report a patient with metastatic HCC who received regorafenib in the setting of the RESORCE trial.
RESULTS
A brilliant response led to a tumor downstaging and a subsequent adrenal metastasectomy with radical intent.
CONCLUSIONS
New agents will change the therapeutic perspectives in advanced HCC and lead to a higher rate of objective responses, with possibilities of associating systemic therapy and surgery. Thus, the management of HCC will require more and more of an integrated, multidisciplinary and personalized approach.
Collapse